What’s in the Stars? Quality Ratings of Medicare Advantage Plans, 2010
NEW: Foundation brief looks at implications of 2011 quality ratings for Medicare Advantage plans.
View the Latest: Medicare Advantage
Filter
-
-
Summary of Final Regulations Implementing the New Medicare Prescription Drug Benefit
Issue BriefThis document summarizes the final regulations to implement the new Medicare prescription drug benefit. The regulations were published by the Centers for Medicare and Medicaid Services (CMS) as a final rule in the Jan. 28 Federal Register. It provides an overview that allows interested parties to obtain information about specific provisions of the law.
-
The Growth of Private Plans in Medicare, 2006
Issue Brief, details the different types of private plan options available to people on Medicare. These include Medicare Advantage plans (such as Medicare HMOs, PPOs and private fee-for-service plans) and new stand-alone prescription drug plans.
-
Medicare Advantage 2011 Data Spotlights
ReportNow Available: 2012 Medicare Advantage Spotlight: Plan Availability and Premiums The Kaiser Family Foundation has issued a series of data spotlights and issue briefs examining the Medicare Advantage plan options available in 2011 and trends affecting the Medicare Advantage marketplace.
-
Gaps in Medicare Advantage Data Remain Despite CMS Actions to Increase Transparency
Issue BriefThe Centers for Medicare and Medicaid Services has recently taken actions to increase transparency in Medicare Advantage, however substantial data gaps remain that limit the ability of policymakers and researchers to conduct oversight and assess the program's performance, and for Medicare beneficiaries to compare Medicare Advantage plans offered in their area.
-
Ending COVID-19 Emergency Declarations Will Bring an End to Flexibilities that Aided Patients, Providers, Insurers, and Public Programs in Responding to the Pandemic
News ReleaseWhen the federal government ends COVID-19 emergency declarations that were declared in the early days of the pandemic, it will bring to a close several changes that were enacted temporarily to enable the U.S. health care system to better deal with the crisis.
-
The Uncertain Future of Medicare’s Stand-Alone Prescription Drug Plan Market and Why It Matters
Issue BriefThis brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want prescription drug coverage but also for the viability of traditional Medicare as an option vis a vis Medicare Advantage.
-
A Small Share of People with Medicare Advantage or Stand-alone Medicare Part D Coverage Voluntarily Switch Plans During Open Enrollment
News ReleaseA new KFF analysis finds that a relatively small share of people with Medicare Advantage or stand-alone Medicare Part D prescription drug coverage voluntarily switch plans during Medicare’s open enrollment period, which runs annually from Oct. 15 to Dec. 7.
-
Issue Briefs Describe Changes in Private Plan Market and Effects on Medicare Beneficiaries
Issue BriefThese two issue briefs describe the different types of private plan options available to people on Medicare, identify key characteristics of the organizations offering the new Medicare drug benefit, and analyze how companies are positioning themselves to attract Medicare enrollees.
-
Private Fee-For-Service Plans In Medicare: Rapid Growth and Future Implications
EventKaiser Family Foundation Vice President Patricia Neuman, Ph.D., testified May 2007 before the House Ways and Means Subcommittee on Health on the rapid growth of private fee-for-service plans in the Medicare program and its implications for seniors and people with disabilities. Dr. Neuman is director of the Foundation's Medicare Policy Project. Testimony (.